KARACHI: Ferozsons Laboratories Limited has obtained the manufacturing licence, along with the requisite production process technology from Gilead Sciences Inc, to manufacture an authorised generic version of ‘Sovaldi’ in Pakistan.

The medicine used in the treatment of Hepatitis C Virus (HCV) will be produced under the brand name of Savera (Sofosbuvir 400mg) tablets, which will be available at a retail market price of Rs5,868 per 28 tablets. Analysts contend that ‘Sovaldi’ is available in the country at Rs32,500 per 28 tablets.

“The availability of an authorised generic version of Sovaldi at such a reduced price will further expand quality treatment access to HCV cure for patents in the country,” the company stated in a filing with the PSX on Monday.

For the quarter ended Mar 31, 2016, Ferozsons’ net sales grew by 109 per cent over the corresponding period last year. At the consolidated group level, net sales showed an increase of 155pc for the nine months and 82pc for the third quarter over the same corresponding period last year. “This growth in the company’s topline is largely due to its portfolio of imported products, particularly its franchise from Gilead Sciences Inc,” the company said.

Ferozsons’ chairperson Mrs Akhter Khalid Waheed had stated in the earlier released quarterly review on the accounts: “In recent months, the Drug Regulatory Authority of Pakistan has granted registration to several generics of Sofosbuvir at a significantly lower price than Sovaldi. At the same time, the company has also become the first Pakistani manufacturer to obtain a licence and the requisite production process technology from Gilead Science to manufacture Sovaldi in Pakistan under the brand name Savera”.

Published in Dawn, May 17th, 2016

Opinion

Civil liberties
23 Oct 2021

Civil liberties

The late I.A. Rehman is esteemed on both sides of the border.
The Hamza factor
Updated 23 Oct 2021

The Hamza factor

A new story is quietly unfolding inside the PML-N and there may yet be a surprise twist.
What should Imran Khan do?
Updated 23 Oct 2021

What should Imran Khan do?

Making a mishmash of religion and politics won’t turn Pakistan into a welfare state. Here’s what can.
Afghan health crises
Updated 22 Oct 2021

Afghan health crises

The condition and prospects of Afghanistan’s health sector are complex and grave.

Editorial

A final push
Updated 23 Oct 2021

A final push

PAKISTAN’S hopes of exiting the so-called FATF grey list have been shattered once again. The global money...
23 Oct 2021

Kabul visit

FOREIGN MINISTER Shah Mahmood Qureshi’s flying visit to Kabul on Thursday is the first official high-level...
23 Oct 2021

Baqir’s blooper

THE remarks made by State Bank governor Reza Baqir at a London press conference have hit a raw nerve in Pakistan. In...
Spate of attacks
Updated 22 Oct 2021

Spate of attacks

Following a near-constant decline since 2016, the year 2021 has witnessed a precipitous rise in violence-related fatalities in KP.
22 Oct 2021

Libel suits

THE outcome of two libel cases recently decided by courts in England should be edifying for the government — if it...
22 Oct 2021

Education losses

A NEW report on the education losses suffered by Pakistani children due to pandemic-induced school closures sheds...